Clinical Trial Update: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2, Phase 3]

View source ↗

Summary

A pediatric Phase 2/3 trial of eculizumab for relapsing neuromyelitis optica spectrum disorder was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-09-25